Role of HBsAg Testing in the Management of Patients with Chronic HBV
July 2019
DOI: 10.1007/s11901-019-00484-y
Tzu-Chan HongHung-Chih YangJia-Horng KaoJia-Horng Kao
Role of HBsAg Testing in the Management of Patients with Chronic HBV
Abstract
Purpose of Review HBsAg has been an important serological marker for the diagnosis of hepatitis B virus (HBV) infection. Recently, HBsAg quantification has been utilized to predict the disease activity and the response to antiviral treatment. This review aims to update the clinical utility of HBsAg quantification in the management of chronic hepatitis B (CHB). Recent Findings HBsAg level varies across different phases of the natural history of CHB, highest in the immune-tolerant phase and lowest in inactive carriers. HBsAg level is useful to stratify the risk of hepatocellular carcinoma in low-viremic patients. HBsAg level also helps predict the HBsAg loss in HBeAg-negative patients. Moreover, baseline level and on-treatment kinetics of HBsAg are associated with the treatment response to pegylated interferon and nucleos(t)ide analogs in both HBeAg-positive and HBeAg-negative patients. Finally, HBsAg level can serve as a therapeutic endpoint marker for evaluating novel curative agents against HBV infection. Summary HBsAg quantification can help guide the management of CHB.作者: StephenW 时间: 2019-8-9 21:33
HBsAg检测在慢性HBV患者管理中的作用
2019年7月
DOI：10.1007 / s11901-019-00484-y
Tzu-Chan HongHung-Chih YangJia-Horng KaoJia-Horng Kao